Procyon Corporation 2024 10-K Review

Introduction

Procyon Corporation, a Colorado-based company, consolidates the operations of its subsidiaries, AMERX Health Care Corporation and Sirius Medical Supply, Inc. The company primarily operates in the medical products industry, focusing on wound and skin care products. This review will delve into the company's 2024 10-K filing, analyzing its business operations, financial performance, risk factors, and overall investment potential.

Warren.AI 💰 5.5 / 10

Business Overview

Procyon Corporation, through its subsidiary AMERX, develops and markets a range of medical products used in the treatment of wounds, ulcers, and other skin conditions. The company's product lines include AMERIGEL, HELIX3 Bioactive Collagen, EXTREMIT-EASE Compression Garment, and Advantagen Surgical Collagen. These products are distributed to healthcare institutions, retail pharmacies, and directly to consumers via online platforms.

AMERX has expanded its product offerings over the years, introducing new products like the HELIX3 Collagen Gel and Advantagen Surgical Collagen. The company has also secured Medicare reimbursement approval for several of its products, which is a significant advantage in the healthcare market.

Financial Performance

Revenue and Profitability

In fiscal 2024, Procyon reported net sales of approximately $4.98 million, a 6% increase from the previous year. Despite the increase in sales, the company recorded a net loss of approximately $341,000, compared to a net loss of $50,000 in fiscal 2023. The increase in net loss is attributed to higher operating expenses, which rose by $456,000, primarily due to increased salaries, benefits, and marketing expenses.

Cash Flow and Liquidity

Procyon's cash flow from operating activities was negative, with a cash outflow of approximately $61,000 in 2024. The company maintained a cash balance of $326,000 at the end of the fiscal year, with additional liquidity from certificates of deposit amounting to $583,000. The company has no significant external cash needs anticipated for fiscal 2025.

Balance Sheet Strength

The company's balance sheet shows total assets of $3.2 million and total liabilities of $917,000, resulting in a stockholders' equity of $2.29 million. The company has a line of credit of $250,000, which remains undrawn, providing additional financial flexibility.

Risk Factors

Procyon faces several risk factors, including reliance on a single manufacturer for its wound care products, which could impact operations if disrupted. The company also faces competitive pressures in the medical products market and regulatory compliance challenges, particularly with the FDA.

Cybersecurity threats are another concern, although the company has not experienced significant impacts from such threats to date. Procyon is actively working to enhance its cybersecurity measures and compliance with evolving regulations.

Investment Potential

Procyon Corporation presents a mixed investment potential. The company's steady revenue growth and product expansion efforts are positive indicators. However, the consistent net losses and reliance on a single manufacturer pose significant risks. The company's financial position is stable, with adequate liquidity and no significant debt, but the profitability challenges need to be addressed.

Conclusion

In conclusion, Procyon Corporation's 2024 10-K filing reveals a company with growth potential but facing significant challenges. The company's focus on expanding its product lines and securing Medicare reimbursement codes is commendable. However, the financial losses and operational risks require careful consideration by potential investors.

Overall, Procyon Corporation receives an investment score of 5.5 out of 10, indicating moderate investment potential with notable risks. Investors should weigh the company's growth prospects against its financial and operational challenges before making investment decisions.